A primer on a preclinical gene‑therapy report exploring a single‑dose IV approach to lower tau in primate brains, and why delivery matters.
Key Takeaways
- Equally notable is how the therapy gets there
- Brain is notoriously difficult to reach because of the blood-brain barrier
- For years, Alzheimer’s research has revolved around amyloid plaques